Continuous evolution of magnetic resonance imaging in multiple sclerosis

por Tallantyre, E. C., Robertson, N. P.
Publicado 2016

Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies

por Allman, M., Tallantyre, E., Robertson, N. P.
Publicado 2022

Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation

por Tallantyre, E. C., Whittam, D. H., Jolles, S., Paling, D., Constantinesecu, C., Robertson, N. P., Jacob, A.
Publicado 2018

Correction to: Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation

por Tallantyre, E. C., Whittam, D. H., Jolles, S., Paling, D., Constantinescu, C., Robertson, N. P., Jacob, A.
Publicado 2018

KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis

por Hares, Kelly, Kemp, K., Loveless, S., Rice, C. M., Scolding, N., Tallantyre, E., Robertson, N., Wilkins, A.
Publicado 2021

Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviors and access to disease-modifying therapies

por Beesley, R., Cauchi, M., Davies, L., Upcott, M., Norton, E., Loveless, S., Anderson, V., Wynford-Thomas, R., Pickersgill, T.P., Uzochukwu, E., Wardle, M., Robertson, N.P., Tallantyre, E., Willis, M.D.
Publicado 2022